WEXFORD,
Pa., June 14, 2023 /PRNewswire/ -- Coeptis
Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or the
"Company"), a biopharmaceutical company developing innovative cell
therapy platforms for cancer, today announced the pricing of an
underwritten offering for gross proceeds of approximately
$3.5 million to a single healthcare
focused investor prior to deducting underwriting discounts and
commissions and offering expenses.
The offering is comprised of (i) 2,150,000 shares of common
stock, (ii) 1,350,000 pre-funded warrants, (iii) 3,062,500 Series A
Warrants with an exercise price of $1.65 per share and a term of five years
following the initial exercise date, and (iv) 3,062,500 Series B
Warrants with an exercise price of $1.65 per share and a term of five years
following the initial exercise date. The warrants issued in this
offering are fixed priced and do not contain any variable pricing,
resets or priced based anti-dilution features. The pre-funded
warrant is exercisable at $0.0001.
The closing of the offering is expected to take place on or about
June 16, 2023, subject to the
satisfaction or waiver of customary closing conditions.
Ladenburg Thalmann & Co. Inc. is acting as sole book-running
manager in connection with this offering.
The securities are being offered pursuant to a registration
statement on Form S-1 (File No. 333-269782), which was declared
effective by the United States Securities and Exchange Commission
("SEC") on June 13, 2023, and related
MEF registration statements on Form S-1 that was filed with the SEC
on June 13, 2023 and June 14, 2023.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy, nor will there be any sales of
these securities in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of such jurisdiction. The
offering is being made solely by means of a prospectus. A
preliminary prospectus relating to the proposed offering was filed
with the SEC on June 13, 2023 and is
available on the SEC's website located at http://www.sec.gov. A
final prospectus relating to this offering will be filed by Coeptis
with the SEC. When available, copies of the final prospectus can be
obtained at the SEC's website at http://www.sec.gov or from
Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth
Avenue, 4th Floor, New York, New
York 10019 or by email at prospectus@ladenburg.com.
About Coeptis Therapeutics Holdings, Inc.
Coeptis
Therapeutics Holdings, Inc., together with its
subsidiaries including Coeptis Therapeutics,
Inc. and Coeptis Pharmaceuticals,
Inc., (collectively "Coeptis"), is a biopharmaceutical
company developing innovative cell therapy platforms for cancer
that have the potential to disrupt conventional treatment paradigms
and improve patient outcomes. Coeptis' product portfolio and rights
are highlighted by a universal, multi-antigen CAR T technology
licensed from the University of
Pittsburgh (SNAP-CAR), and intellectual property and
knowhow related to the GEAR™ cell therapy and companion diagnostic
platforms, which Coeptis is developing with VyGen-Bio and
leading medical researchers at the Karolinska Institutet.
Coeptis' business model is designed around maximizing the value of
its current product portfolio and rights through in-license
agreements, out-license agreements and co-development
relationships, as well as entering into strategic partnerships to
expand its product rights and offerings, specifically those
targeting cancer. The Company is headquartered in Wexford, PA.
For more information on Coeptis
visit https://coeptistx.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in
connection therewith contain or may contain "forward-looking
statements" (as defined in Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements
concerning our plans, objectives, goals, strategies, future events
or performance, and underlying assumptions, and other statements
that are other than statements of historical facts. When we use
words such as "may," "will," "intend," "should," "believe,"
"expect," "anticipate," "project," "estimate" or similar
expressions that do not relate solely to historical matters, we are
making forward-looking statements. Forward-looking statements are
not a guarantee of future performance and involve significant risks
and uncertainties that may cause the actual results to differ
materially and perhaps substantially from our expectations
discussed in the forward-looking statements. Factors that may cause
such differences include but are not limited to: (1) the inability
to maintain the listing of the Company's securities on the Nasdaq
Global Market; (2) the risk that currently explored expansion
opportunities, if consummated, disrupts current plans and
operations of Company; (3) the inability to recognize the
anticipated benefits of the recently closed business combination,
which may be affected by, among other things, competition, the
ability of the Company to grow and manage growth economically and
hire and retain key employees; (4) the risks that the Company's
products in development or those targeted to enter the clinical
trial phase fail clinical trials or are not approved by the U.S.
Food and Drug Administration or other applicable regulatory
authorities; (5) costs related to our ongoing asset development
plans and our focus on business expansion opportunities; (6)
changes in applicable laws or regulations; (7) the possibility that
the Company may be adversely affected by other economic, business,
and/or competitive factors; and (8) the impact of the global
COVID-19 pandemic on any of the foregoing risks and other risks and
uncertainties identified in the Company's filings with the
Securities and Exchange Commission (the "SEC"). The foregoing list
of factors is not exclusive. All forward-looking statements are
subject to significant uncertainties and risks including, but not
limited, to those risks contained or to be contained in reports and
other filings filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance
upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings made or
to be made with the SEC, which are available for review
at www.sec.gov. We undertake no obligation to publicly revise
these forward-looking statements to reflect events or circumstances
that arise after the date hereof unless required by applicable
laws, regulations, or rules.
CONTACTS
Coeptis Therapeutics, Inc.
Andy Galy, Sr. VP of
Communications
andy.galy@coeptistx.com
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
dboateng@tiberend.com
Media
David Schemelia
dschemelia@tiberend.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-holdings-inc-announces-pricing-of-3-5-million-underwritten-offering-301850794.html
SOURCE Coeptis Therapeutics